Recognizing the expertise, proven success record and promise of further discovery, the Leukemia & Lymphoma Society (LLS) has awarded a Specialized Center of Research (SCOR) grant to a 12-member team of researchers at Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, and Brigham and Women’s Hospital. The team is led by Stephen D. Nimer, M.D., director of Sylvester.
New findings by researchers at Sylvester Comprehensive Cancer Center may prove to be an important solution to one of the more difficult problems faced in the field of precision medicine when it comes to treating cancer. An article reporting their findings, “Discordancy Partitioning for Validating Potentially Inconsistent Pharmacogenomic Studies,” was published online November 9 by Scientific Reports.
A collaborative study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues has identified a novel therapeutic target for incurable prostate cancer. The research found a critical role for thioredoxin-1, a protein that protects cells from oxidative stress, in the progression of prostate cancer to the incurable castration-resistant stage.
With the telltale beating of a single drum and a tap on the shoulder with an iron arrow, members of the Iron Arrow Honor Society renewed one of the U’s greatest traditions during homecoming week. Marching across the Coral Gables and medical campuses in a solemn procession, they bestowed a leading University of Miami honor on 20 lucky recipients.
Angelique Muniz boxed in college, and since then she has kept physically active at a local gym, mixing cardio kickboxing with Zumba and yoga classes. But she fought the fight of her life two years ago, when an irritation in her throat turned out to be stage 3 oral cancer. Her aggressive cancer required an aggressive response: the removal and reconstruction of half of her tongue, followed by radiation and extensive therapy.
Pique Therapeutics, Inc. has announced encouraging results in a clinical trial of PT 107, an immunotherapy developed by a renowned scientist at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine to treat non-small cell lung cancer (NSCLC), the most common form of the disease.
Wael El-Rifai, M.D., Ph.D., an internationally renowned physician-scientist, has joined the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine as co-leader of the Tumor Biology Program and associate director for Program Development. His departmental appointments are professor and associate vice chair of surgery, and professor of biochemistry and molecular biology.
Denise “Denny” Feinsilver’s legacy as a fierce advocate and fundraiser for cancer research is now a permanent part of Sylvester Comprehensive Cancer Center. The Denny Feinsilver Patient Reception Area was formally dedicated October 2 during a ceremony that included her family and friends, and the leadership of Sylvester and the University of Miami Miller School of Medicine.
Sylvester Comprehensive Cancer Center is one of a very limited number of sites in the United States that will provide a newly approved innovative treatment for diffuse large B cell lymphoma — an aggressive form of blood cancer. It takes a patient’s own immune cells (T cells), and uses state-of-the-art genetic engineering to transform them into a supercharged cancer-hunting cellular therapy.
Starting in 2018, Comic Cure, a company that uses the power of laughter to uplift and engage social communities around important causes, will partner with Sylvester Comprehensive Cancer Center to produce quarterly comedy shows that will be broadcast live to all seven Sylvester locations throughout South Florida. “If laughter is the best medicine, then we are the pharmacy,” said Comic Cure co-founder Benjamin Leis.